Join our daily newsletter At The Bell to receive exclusive market insights
- Paradigm Biopharmaceuticals (PAR) begins dosing subjects in phase 3 of its clinical trial to test its Zilosul treatment for knee osteoarthritis pain
- The aim of the study is to measure the change in pain and function when receiving the injection of Zilosul, as opposed to the placebo
- The study is currently enrolling subjects in eight sites across Australia, as well as 21 of 56 selected sites in the US
- A key focus for the company has been clinical trial site activation, which has enabled a large pool of potential candidates to be screened at activated sites
- Shares are trading 4.47 per cent higher at $1.29 each at 12:30 pm AEST
Paradigm Biopharmaceuticals (PAR) has started dosing subjects in phase 3 of its clinical trial to test its Zilosul drug in treatment of pain associated with knee osteoarthritis.
The aim of the study is to measure the change in pain and function when receiving the injection of Zilosul, as opposed to the placebo.
The study is currently enrolling subjects in eight sites across Australia, as well as 21 of 56 selected sites in the US.
A key focus for the company has been clinical trial site activation, which has enabled a large pool of potential candidates to be screened at activated sites.
Paradigm said it will continue site activations in the US, while also starting its search for sites in the UK and Europe.
“The Paradigm clinical team has been working tirelessly to initiate and activate sites throughout the US and we are seeing a large number of subjects entering the screening phase throughout the US,” Chief Medical Officer and interim CEO, Dr Donna Skerrett said.
“We look forward to continuing the strong momentum in the phase 3 program and reporting important recruitment milestones to our shareholders.”
Shares were trading 4.47 per cent higher at $1.29 each at 11:30 am AEST.
